Global Literature Review

Maintain compliance and enhance safety oversight with expert-driven literature evaluation and reporting.

Person working on desktop and laptop devices

Literature Search

The review of worldwide scientific literature is an essential part of the ongoing safety surveillance of medicinal products, regardless of commercial status. To ensure compliance with regulatory legislation worldwide, it is essential that global and local literature screening, where applicable, is regularly conducted to identify reportable ICSRs and safety relevant information.

Our experienced team at ProPharma can support you or assume full responsibility for these activities to ensure your PV program adheres to the global regulatory requirements.

In addition, our services are cost-effective, and we are able to conduct global literature surveillance of large bibliographical databases including Medline® via the Biologit platform.

We have extensive experience in developing robust search strategies for our clients and providing results from these searches according to an agreed upon periodicity. We can perform the review and assessment of identified literature articles and ensure the efficient and auditable documentation of results.

We have experience and well-established processes for conducting local literature screenings. We can support you in the set-up and conduct, including the identification of relevant local databases and journals, and translation of articles, if needed.

For Marketing Authorization Holders (MAHs) with active substances included in the EMA’s Medical Literature Monitoring (MLM) list, we perform EudraVigilance checks using the ICSR Export module based on the frequency contracted. In addition, we provide local literature searches in relevant local scientific and medical journals in countries where your product is marketed and where this is legally required.

Woman typing on computer keyboard

News & Insights

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI Use in Manufacturing

April 22, 2026

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI ...

The FDA's warning letter to Purolea Cosmetics Lab highlights the need for rigorous AI governance in pharmaceutical manufacturing. Compliance is crucial for product quality and safety.

Offshoring Medical Information Services: A Breakthrough Trend to Achieve 24/7 Global Market Reach

April 20, 2026

Offshoring Medical Information Services: A Breakthrough Trend to Achieve 24/7 Gl...

Explore the benefits of offshoring medical information services, enhancing global support and operational flexibility for healthcare and pharmaceutical companies.

Preparing for EMA Policy 0070: How to Stay Ahead of the Anonymization Curve

April 16, 2026

Preparing for EMA Policy 0070: How to Stay Ahead of the Anonymization Curve

Prepare for EMA Policy 0070 by understanding anonymization requirements, project management strategies, and best practices to ensure a smooth submission process.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Case Study How a Novel Real World Evidence Strategy Helped Bring a Class III Device to Market - ProPharma

March 23, 2026

Real World Evidence for Class III Devices: A Smarter Path to PMA

Struggling to generate clinical evidence for Class III devices without costly, multi-year trials? Discover how ProPharma helped an orthopedic device company leverage existing registry data to support...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI Use in Manufacturing

April 22, 2026

When AI Meets CGMP: Lessons from FDA's First Warning Letter on Non-Compliant AI ...

The FDA's warning letter to Purolea Cosmetics Lab highlights the need for rigorous AI governance in pharmaceutical manufacturing. Compliance is crucial for product quality and safety.

Offshoring Medical Information Services: A Breakthrough Trend to Achieve 24/7 Global Market Reach

April 20, 2026

Offshoring Medical Information Services: A Breakthrough Trend to Achieve 24/7 Gl...

Explore the benefits of offshoring medical information services, enhancing global support and operational flexibility for healthcare and pharmaceutical companies.

Preparing for EMA Policy 0070: How to Stay Ahead of the Anonymization Curve

April 16, 2026

Preparing for EMA Policy 0070: How to Stay Ahead of the Anonymization Curve

Prepare for EMA Policy 0070 by understanding anonymization requirements, project management strategies, and best practices to ensure a smooth submission process.

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice President, Labeling & Strategy to Advance Strategic Labeling & Promotional Review

July 8, 2025

ProPharma Appoints Marshall Florence, Former FDA Labeling Expert, as Vice Presid...

ProPharma appoints former FDA labeling expert as VP, Labeling & Strategy, enhancing strategic labeling, promotional review, and regulatory consulting expertise to accelerate drug development and...

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Reducing Patient Burden While Maintaining High-Frequency  Monitoring in a Hemophilia Gene  Therapy Trial

April 20, 2026

Reducing Patient Burden While Maintaining High-Frequency Monitoring in a Hemoph...

Balancing rigorous clinical oversight with patient accessibility is critical in complex gene therapy trials. Intensive early-phase monitoring and complex protocols can place significant burden on...

Case Study Ensure Launch Readiness—Even on the Tightest Timelines

March 30, 2026

Ensure Launch Readiness, Even on the Tightest Timelines

Expediting Promotional Review to Deliver 60+ Materials in Just 4 Weeks When timelines are compressed and stakes are high, promotional review processes can quickly become a bottleneck. This case study...

Case Study How a Novel Real World Evidence Strategy Helped Bring a Class III Device to Market - ProPharma

March 23, 2026

Real World Evidence for Class III Devices: A Smarter Path to PMA

Struggling to generate clinical evidence for Class III devices without costly, multi-year trials? Discover how ProPharma helped an orthopedic device company leverage existing registry data to support...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow